Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3350621 | 0.97 | KDM4E (0.38) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL9842065 | 0.80 | LMNA (0.37) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL1699135 | 0.80 | TSHR (0.42) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL3465587 | 0.80 | LMNA (0.37) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL13544793 | 0.80 | LMNA (0.38) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL804144 | 0.80 | KDM4E (0.54) | KDM4ECYP2C19ALDH1A1TDP1HMGCR | |
| SCHEMBL24709299 | 0.79 | KDM4E (0.33) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL5069470 | 0.78 | KDM4E (0.31) | KDM4ECYP2C19LMNAALOX15BLM | |
| SCHEMBL9688090 | 0.76 | TDP1 (0.43) | KDM4ELMNAALDH1A1HSD17B10TDP1 | |
| SCHEMBL3915051 | 0.76 | LMNA (0.35) | KDM4ECYP2C19LMNAALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-109803948-B | Warming sensation compound | 高砂香料工业株式会社 | 2022-03-01 | — | — | CN | claimed |
| CN-108698992-A | 2- cyano isoindoline derivatives for treating cancer | 特殊治疗有限公司 | 2018-10-23 | — | — | CN | claimed |
| US-20170158684-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2017-06-08 | — | — | US | claimed |
| CN-106262580-A | A kind of coolant agent N (4 methoxyphenyl) using method to menthyl 3 carboxylic acid amides | 安徽丰乐香料有限责任公司 | 2017-01-04 | — | — | CN | claimed |
| CN-103787905-B | A kind of L-menthyl-N, the new synthetic method of N-dimethylsuccinic acid amides | Anhui Fengle Perfume Co., Ltd. (CN) | 2016-04-20 | — | — | CN | claimed |
| CN-105121433-A | Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | KOREA RES INST CHEM TECH | 2015-12-02 | — | — | CN | claimed |
| US-20150336920-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-11-26 | — | — | US | claimed |
| CN-103501780-B | Benzofuran-piperidine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | claimed |
| EP-2933254-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2015-10-21 | — | — | EP | claimed |
| CN-103501780-A | Novel benzofurane-piperidine compounds | HOFFMANN LA ROCHE | 2014-01-08 | — | — | CN | claimed |
| CN-101747455-B | Supported main catalyst for olefin polymerization and preparation method thereof | PETROCHINA CO LTD | 2012-03-07 | — | — | CN | claimed |
| EP-2139894-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | AstraZeneca AB (SE) | 2010-01-06 | — | — | EP | claimed |
| WO-2008114006-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | claimed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| CN-1116192-A | Composition and production method of special spraying fertilizer for crops | SONG KAIQUAN (CN) | 1996-02-07 | — | — | CN | claimed |
| CN-116322326-A | Polyurea/polyurethane microcapsules | 西姆莱斯股份公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-0062161-B1 | SYNTHESIS OF AMIDES USING CARBAMIC-ACID SALTS | UNION CARBIDE CORPORATION (US) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | KDM4E 4405/4885CYP2C19 4273/4885LMNA 294/4885 |
| US-20170158684-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | RNASE1, HTRA1, IAPP | KDM4E 4532/4885CYP2C19 2342/4885LMNA 3186/4885 |
| US-20150336920-A1 | NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | RNASE1, HTRA1, IAPP | KDM4E 4532/4885CYP2C19 2342/4885LMNA 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.